Abstract | RATIONALE: OBJECTIVE: METHODS: MEASUREMENTS AND MAIN RESULTS: CONCLUSIONS: These results suggest that IMD-0354 might be useful to ameliorate the inflammation in the lungs induced by fibrotic injury and the subsequent fibrogenesis via inhibiting the expression of profibrotic cytokines related to the activation of NF-kappaB.
|
Authors | Mami Inayama, Yasuhiko Nishioka, Momoyo Azuma, Susumu Muto, Yoshinori Aono, Hideki Makino, Kenji Tani, Hisanori Uehara, Keisuke Izumi, Akiko Itai, Saburo Sone |
Journal | American journal of respiratory and critical care medicine
(Am J Respir Crit Care Med)
Vol. 173
Issue 9
Pg. 1016-22
(May 01 2006)
ISSN: 1073-449X [Print] United States |
PMID | 16456147
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzamides
- Interleukin-1
- Interleukin-1beta
- Peptide Fragments
- Tumor Necrosis Factor-alpha
- interleukin-1beta (163-171)
- Bleomycin
- N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide
- I-kappa B Kinase
|
Topics |
- Animals
- Benzamides
(therapeutic use)
- Bleomycin
- Bronchoalveolar Lavage Fluid
(cytology)
- Female
- I-kappa B Kinase
(antagonists & inhibitors)
- Interleukin-1
(metabolism)
- Interleukin-1beta
- Mice
- Mice, Inbred C57BL
- Peptide Fragments
(metabolism)
- Pulmonary Alveoli
(metabolism, pathology)
- Pulmonary Fibrosis
(drug therapy, metabolism, pathology)
- Tumor Necrosis Factor-alpha
(metabolism)
|